Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers

Marline G. Harmsen, Jurgen M.J. Piek, Johan Bulten, Murray J. Casey, Timothy R. Rebbeck, Marian J. Mourits, Mark H. Greene, Brigitte F.M. Slangen, Marc van Beurden, Leon F.A.G. Massuger, Nicoline Hoogerbrugge, Joanne A. de Hullu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal carcinomatosis occasionally is diagnosed. METHODS: The literature was searched for BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-reducing surgery. The authors were asked for additional data. Clinical and histopathological data were descriptively analyzed. Cases were compared with a single-institution control cohort. RESULTS: Of 36 cases, 86.1% concerned BRCA1 mutation carriers. The median age of the patients was 52 years (range, 30-71 years) at the time of risk-reducing surgery and 60 years (range, 37-75 years) at the time of diagnosis of peritoneal carcinomatosis. The median interval between the 2 events was 54.5 months (range, 11-292 months). Peritoneal carcinomatosis was mostly high-grade serous carcinoma. Histopathological details of the RRSO specimens were retrieved in 8 cases; 5 (62.5%) were found to have serous tubal intraepithelial carcinoma and 1 had epithelial atypia. Cases were older (P = .025) at the time of risk-reducing surgery and harbored more serous tubal intraepithelial carcinomas (P<.001) compared with women from the control cohort. CONCLUSIONS: Metachronous peritoneal carcinomatosis after risk-reducing surgery occurs predominantly in BRCA1 mutation carriers, usually within 5 years. Data have suggested that surgery at a younger age lowers the rates of peritoneal carcinomatosis. These data can be used in the gynecologic counseling of BRCA1/2 mutation carriers. RRSO should include complete salpingectomy. Detailed histopathological examination of specimens removed during RRSO is essential.

Original languageEnglish (US)
JournalCancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Carcinoma
Mutation
Ovariectomy
Carcinoma in Situ
Salpingectomy
Counseling

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Harmsen, M. G., Piek, J. M. J., Bulten, J., Casey, M. J., Rebbeck, T. R., Mourits, M. J., ... de Hullu, J. A. (Accepted/In press). Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. Cancer. https://doi.org/10.1002/cncr.31211

Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. / Harmsen, Marline G.; Piek, Jurgen M.J.; Bulten, Johan; Casey, Murray J.; Rebbeck, Timothy R.; Mourits, Marian J.; Greene, Mark H.; Slangen, Brigitte F.M.; van Beurden, Marc; Massuger, Leon F.A.G.; Hoogerbrugge, Nicoline; de Hullu, Joanne A.

In: Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Harmsen, MG, Piek, JMJ, Bulten, J, Casey, MJ, Rebbeck, TR, Mourits, MJ, Greene, MH, Slangen, BFM, van Beurden, M, Massuger, LFAG, Hoogerbrugge, N & de Hullu, JA 2018, 'Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers', Cancer. https://doi.org/10.1002/cncr.31211
Harmsen, Marline G. ; Piek, Jurgen M.J. ; Bulten, Johan ; Casey, Murray J. ; Rebbeck, Timothy R. ; Mourits, Marian J. ; Greene, Mark H. ; Slangen, Brigitte F.M. ; van Beurden, Marc ; Massuger, Leon F.A.G. ; Hoogerbrugge, Nicoline ; de Hullu, Joanne A. / Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers. In: Cancer. 2018.
@article{18095b4521714bea8e568a6994852eab,
title = "Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers",
abstract = "BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal carcinomatosis occasionally is diagnosed. METHODS: The literature was searched for BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-reducing surgery. The authors were asked for additional data. Clinical and histopathological data were descriptively analyzed. Cases were compared with a single-institution control cohort. RESULTS: Of 36 cases, 86.1{\%} concerned BRCA1 mutation carriers. The median age of the patients was 52 years (range, 30-71 years) at the time of risk-reducing surgery and 60 years (range, 37-75 years) at the time of diagnosis of peritoneal carcinomatosis. The median interval between the 2 events was 54.5 months (range, 11-292 months). Peritoneal carcinomatosis was mostly high-grade serous carcinoma. Histopathological details of the RRSO specimens were retrieved in 8 cases; 5 (62.5{\%}) were found to have serous tubal intraepithelial carcinoma and 1 had epithelial atypia. Cases were older (P = .025) at the time of risk-reducing surgery and harbored more serous tubal intraepithelial carcinomas (P<.001) compared with women from the control cohort. CONCLUSIONS: Metachronous peritoneal carcinomatosis after risk-reducing surgery occurs predominantly in BRCA1 mutation carriers, usually within 5 years. Data have suggested that surgery at a younger age lowers the rates of peritoneal carcinomatosis. These data can be used in the gynecologic counseling of BRCA1/2 mutation carriers. RRSO should include complete salpingectomy. Detailed histopathological examination of specimens removed during RRSO is essential.",
author = "Harmsen, {Marline G.} and Piek, {Jurgen M.J.} and Johan Bulten and Casey, {Murray J.} and Rebbeck, {Timothy R.} and Mourits, {Marian J.} and Greene, {Mark H.} and Slangen, {Brigitte F.M.} and {van Beurden}, Marc and Massuger, {Leon F.A.G.} and Nicoline Hoogerbrugge and {de Hullu}, {Joanne A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cncr.31211",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers

AU - Harmsen, Marline G.

AU - Piek, Jurgen M.J.

AU - Bulten, Johan

AU - Casey, Murray J.

AU - Rebbeck, Timothy R.

AU - Mourits, Marian J.

AU - Greene, Mark H.

AU - Slangen, Brigitte F.M.

AU - van Beurden, Marc

AU - Massuger, Leon F.A.G.

AU - Hoogerbrugge, Nicoline

AU - de Hullu, Joanne A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal carcinomatosis occasionally is diagnosed. METHODS: The literature was searched for BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-reducing surgery. The authors were asked for additional data. Clinical and histopathological data were descriptively analyzed. Cases were compared with a single-institution control cohort. RESULTS: Of 36 cases, 86.1% concerned BRCA1 mutation carriers. The median age of the patients was 52 years (range, 30-71 years) at the time of risk-reducing surgery and 60 years (range, 37-75 years) at the time of diagnosis of peritoneal carcinomatosis. The median interval between the 2 events was 54.5 months (range, 11-292 months). Peritoneal carcinomatosis was mostly high-grade serous carcinoma. Histopathological details of the RRSO specimens were retrieved in 8 cases; 5 (62.5%) were found to have serous tubal intraepithelial carcinoma and 1 had epithelial atypia. Cases were older (P = .025) at the time of risk-reducing surgery and harbored more serous tubal intraepithelial carcinomas (P<.001) compared with women from the control cohort. CONCLUSIONS: Metachronous peritoneal carcinomatosis after risk-reducing surgery occurs predominantly in BRCA1 mutation carriers, usually within 5 years. Data have suggested that surgery at a younger age lowers the rates of peritoneal carcinomatosis. These data can be used in the gynecologic counseling of BRCA1/2 mutation carriers. RRSO should include complete salpingectomy. Detailed histopathological examination of specimens removed during RRSO is essential.

AB - BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1/2 mutation carriers because of their increased risk of ovarian carcinoma. Despite RRSO, metachronous peritoneal carcinomatosis occasionally is diagnosed. METHODS: The literature was searched for BRCA1/2 mutation carriers with peritoneal carcinomatosis after risk-reducing surgery. The authors were asked for additional data. Clinical and histopathological data were descriptively analyzed. Cases were compared with a single-institution control cohort. RESULTS: Of 36 cases, 86.1% concerned BRCA1 mutation carriers. The median age of the patients was 52 years (range, 30-71 years) at the time of risk-reducing surgery and 60 years (range, 37-75 years) at the time of diagnosis of peritoneal carcinomatosis. The median interval between the 2 events was 54.5 months (range, 11-292 months). Peritoneal carcinomatosis was mostly high-grade serous carcinoma. Histopathological details of the RRSO specimens were retrieved in 8 cases; 5 (62.5%) were found to have serous tubal intraepithelial carcinoma and 1 had epithelial atypia. Cases were older (P = .025) at the time of risk-reducing surgery and harbored more serous tubal intraepithelial carcinomas (P<.001) compared with women from the control cohort. CONCLUSIONS: Metachronous peritoneal carcinomatosis after risk-reducing surgery occurs predominantly in BRCA1 mutation carriers, usually within 5 years. Data have suggested that surgery at a younger age lowers the rates of peritoneal carcinomatosis. These data can be used in the gynecologic counseling of BRCA1/2 mutation carriers. RRSO should include complete salpingectomy. Detailed histopathological examination of specimens removed during RRSO is essential.

UR - http://www.scopus.com/inward/record.url?scp=85040168578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040168578&partnerID=8YFLogxK

U2 - 10.1002/cncr.31211

DO - 10.1002/cncr.31211

M3 - Article

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -